- Home
- AORT vs EWTX Comparison
AORT vs EWTX Comparison
Compare AORT & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AORT
- EWTX
- Stock Information
- Founded
- AORT 1984
- EWTX 2017
- Country
- AORT United States
- EWTX United States
- Employees
- AORT N/A
- EWTX N/A
- Industry
- AORT Medical/Dental Instruments
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- AORT Health Care
- EWTX Health Care
- Exchange
- AORT Nasdaq
- EWTX Nasdaq
- Market Cap
- AORT 1.0B
- EWTX 1.2B
- IPO Year
- AORT 1993
- EWTX 2021
- Fundamental
- Price
- AORT $28.91
- EWTX $14.58
- Analyst Decision
- AORT Strong Buy
- EWTX Buy
- Analyst Count
- AORT 5
- EWTX 8
- Target Price
- AORT $31.40
- EWTX $40.13
- AVG Volume (30 Days)
- AORT 520.4K
- EWTX 1.2M
- Earning Date
- AORT 05-05-2025
- EWTX 05-08-2025
- Dividend Yield
- AORT N/A
- EWTX N/A
- EPS Growth
- AORT N/A
- EWTX N/A
- EPS
- AORT N/A
- EWTX N/A
- Revenue
- AORT $390,084,000.00
- EWTX N/A
- Revenue This Year
- AORT $11.21
- EWTX N/A
- Revenue Next Year
- AORT $10.77
- EWTX N/A
- P/E Ratio
- AORT N/A
- EWTX N/A
- Revenue Growth
- AORT 5.94
- EWTX N/A
- 52 Week Low
- AORT $21.97
- EWTX $10.60
- 52 Week High
- AORT $32.33
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- AORT 77.73
- EWTX 41.67
- Support Level
- AORT $23.15
- EWTX $13.82
- Resistance Level
- AORT $24.23
- EWTX $17.30
- Average True Range (ATR)
- AORT 0.93
- EWTX 1.02
- MACD
- AORT 0.70
- EWTX 0.32
- Stochastic Oscillator
- AORT 94.62
- EWTX 30.43
About AORT Artivion Inc.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.